Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43414 | 0.86 | POLB (0.41) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL1746858 | 0.85 | ALDH1A1 (0.35) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL19209537 | 0.85 | APOBEC3G (0.40) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL12092095 | 0.84 | LMNA (0.42) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL42368 | 0.82 | ALDH1A1 (0.44) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL29352062 | 0.82 | ALDH1A1 (0.44) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL2435515 | 0.81 | POLB (0.41) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL29356575 | 0.81 | ALDH1A1 (0.39) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL107907 | 0.81 | ALDH1A1 (0.39) | LMNAEHMT2EHMT1APOBEC3GALDH1A1 | |
| SCHEMBL8328957 | 0.80 | ALDH1A1 (0.39) | LMNAALDH1A1RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210299063-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-09-30 | — | — | US | disclosed |
| US-9944984-B2 | High density DNA array | COMPLETE GENOMICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170152554-A1 | HIGH DENSITY DNA ARRAY | COMPLETE GENOMICS, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| EP-1883410-A2 | ANTIBODY OR ANTIBODY FRAGMENT COUPLED WITH AN IMMUNOGENIC AGENT | INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER) (FR) | 2008-02-06 | — | — | EP | disclosed |
| EP-1758987-A1 | METHODS FOR STEM CELL EXPANSION AND DIFFERENTIATION | PETER MacCALLUM CANCER INSTITUTE (AU) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006125921-A2 | ANTIBODY OR ANTIBODY FRAGMENT COUPLED WITH AN IMMUNOGENIC AGENT | INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER IFREMER (FR) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005105985-A1 | METHODS FOR STEM CELL EXPANSION AND DIFFERENTIATION | PETER MACCALLUM CANCER INSTITUTE (AU) | 2005-11-10 | — | — | WO | disclosed |
| EP-1359937-A4 | ALTERED PEPTIDE LIGANDS | GENZYME CORP (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1359937-A1 | ALTERED PEPTIDE LIGANDS | GENZYME CORPORATION (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002070003-A1 | ALTERED PEPTIDE LIGANDS | GENZYME CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299063-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | LMNA 3666/4885EHMT2 1488/4885EHMT1 1237/4885 |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | LMNA 3666/4885EHMT2 1488/4885EHMT1 1237/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | LMNA 3666/4885EHMT2 1488/4885EHMT1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.